Rabbit Recombinant Monoclonal SUCLA2 antibody - conjugated to Alexa Fluor® 488.
IgG
Rabbit
Alexa Fluor® 488
Ex: 495nm, Em: 519nm
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Liquid
Monoclonal
Application | Reactivity | Dilution info | Notes |
---|---|---|---|
Application Target Binding Affinity | Reactivity Expected | Dilution info - | Notes - |
Application Antibody Labelling | Reactivity Expected | Dilution info - | Notes - |
Select an associated product type
ATP-specific succinyl-CoA synthetase functions in the citric acid cycle (TCA), coupling the hydrolysis of succinyl-CoA to the synthesis of ATP and thus represents the only step of substrate-level phosphorylation in the TCA (PubMed:15877282). The beta subunit provides nucleotide specificity of the enzyme and binds the substrate succinate, while the binding sites for coenzyme A and phosphate are found in the alpha subunit (By similarity).
ATP-specific succinyl-CoA synthetase subunit beta, Succinyl-CoA synthetase beta-A chain, A-SCS, SCS-betaA, SUCLA2
Rabbit Recombinant Monoclonal SUCLA2 antibody - conjugated to Alexa Fluor® 488.
IgG
Rabbit
Alexa Fluor® 488
Ex: 495nm, Em: 519nm
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Liquid
Monoclonal
EPR14924
Affinity purification Protein A
Blue Ice
1-2 weeks
+4°C
-20°C
Upon delivery aliquot
Avoid freeze / thaw cycle, Store in the dark
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for the Abcam trial program.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This supplementary information is collated from multiple sources and compiled automatically.
SUCLA2 also known as succinate-CoA ligase (ADP-forming) subunit beta is an enzyme with a molecular mass of approximately 48 kDa. It plays an important role in the mitochondrial matrix where it participates in the citric acid cycle. The enzyme is found in various tissues with higher expression in muscle and brain tissues. SUCLA2 functions as part of the succinyl-CoA synthetase complex which catalyzes the reversible conversion of succinyl-CoA to succinate with the concurrent substrate-level phosphorylation of GDP to GTP or ADP to ATP depending on tissue type.
The SUCLA2 subunit is essential for energy metabolism. It forms a component of the succinyl-CoA synthetase complex working with the alpha subunit SUCLG1. This complex supports the provision of energy by converting GDP to GTP in processes needing high energy levels critical for maintaining cellular homeostasis. Therefore it especially supports tissues with high energy demands. The action of SUCLA2 links energy production with the metabolic pathways involved in cellular respiration.
SUCLA2 plays a critical role in the citric acid cycle also known as the Krebs cycle. Part of this cycle SUCLA2 contributes to cellular respiration and energy production. The SUCLA2 protein closely interacts with SUCLG1 to form the functional succinyl-CoA synthetase enzyme. Additionally it shows connections to the electron transport chain where the products of its catalysis are used in ATP generation. Defects in these pathways can have widespread effects on cellular energy states and mitochondrial function.
SUCLA2 mutations are linked to mitochondrial DNA depletion syndromes particularly myopathy and encephalopathy. These conditions lead to severe energy metabolism impairments due to faulty mitochondrial function. SUCLA2 has also been associated with Leigh syndrome a neurodegenerative disorder marked by compromised cellular respiration. Such disorders point towards deficient ATP synthesis highlighting the interconnected role of SUCLA2 with other mitochondrial proteins involved in cellular energy metabolism.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com